OKYO PHARMA
Okyo Pharma focuses on novel GPCR based therapeutics for eye diseases of high unmet need and non-opioid analgesics for chronic pain.
OKYO PHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2007-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.okyopharma.com
Total Employee:
11+
Status:
Active
Contact:
44 (0) 207 495 2379
Total Funding:
2.5 M USD
Stock Details
Official Site Inspections
http://www.okyopharma.com Semrush global rank: 5.77 M Semrush visits lastest month: 1.45 K
- Host name: grh59.myukcloud.com
- IP address: 5.134.14.212
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Okyo Pharma"
About - OKYO Pharma
About. OKYO Pharma Ltd. (NASDAQ:OKYO), is a biopharmaceutical company dedicated to developing an innovative treatment for neuropathic corneal pain and dry eye disease. Through its proprietary chemerin peptide, OK-101, the …See details»
Corporate Information - OKYO Pharma
Okyo Pharma - Crunchbase Company Profile & Funding
Organization. Okyo Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email info@okyopharma.com; …See details»
OKYO - OKYO PHARMA LTD. | Company Profile | OTC Markets
Jan 3, 2025 info@okyopharma.com Business Description OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the …See details»
OKYO Pharma Limited - Yahoo Finance Canada
See the company profile for OKYO Pharma Limited (OKYO) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
OKYO Pharma - LinkedIn
OKYO focuses on novel GPCR based therapeutics for eye diseases of unmet need and non-opioid analgesics for chronic pain. OKYO Pharma focuses on: A novel class of membrane …See details»
OKYO Pharma Company Profile - Office Locations, Competitors
Oct 28, 2024 OKYO Pharma is a biopharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain. It develops a lipidated chemerin-peptide …See details»
OKYO Pharma Limited (OKYO) Company Profile & Facts - Yahoo …
See the company profile for OKYO Pharma Limited (OKYO) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Okyo Pharma - businessabc.net
Mar 11, 2025 Otsuka Pharmaceutical Co., Ltd. was founded in 1921 as a small mom-and-pop drug store in Tokyo. Today, the global Otsuka Group, which includes Okyo Pharma, produces …See details»
Company Presentation - OKYO Pharma
Aug 3, 2020 OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is …See details»
OKYO Pharma - VentureRadar
"OKYO Pharma is a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain.See details»
OKYO Pharma (OKYO) Company Profile & Description - Stock …
May 17, 2022 Ticker Symbol: OKYO: Exchange: NASDAQ: Fiscal Year: April - March: Reporting Currency: USD: IPO Price: $4.00: CIK Code: 0001849296: CUSIP Number: 679345108: ISIN ...See details»
OKYO Pharma Limited - Cruelty Free Investing
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the …See details»
OKYO Pharma - Overview, News & Similar companies - ZoomInfo
May 8, 2024 OKYO Pharma Announces Participation in May 2024 Investor Conferences LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited …See details»
Corporate Documents - OKYO Pharma
Corporate Documents. Results of AGM 2024. Notice of AGM: December 2024. Results of AGM 2023. Notice of AGM: December 2023. Registration Statement for former UK shareholders …See details»
OKYO Pharma - Samedan
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application granted by the …See details»
OKYO Pharma - Company Profile - Tracxn
Feb 3, 2025 OKYO Pharma - Developer of therapeutics for the treatment of dry eye disease and chronic pain management. Public Company. Raised funding over 4 rounds. OKYO Pharma …See details»
OKYO Pharma Announces Chairman and CEO Acquire Shares
Jan 31, 2025 OKYO Pharma Limited: Gary S. Jacob, Chief Executive Officer: U.S. 917-497-7560: Business Development & Investor Relations: Paul Spencer +44 (0)20 7495 2379See details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different …See details»
OKYO Pharma Files for Fast Track Designation with FDA for …
Mar 10, 2025 London and New York, NY, March 10, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the …See details»